What is the clinical and cost effectiveness of biomarker-based monitoring, monitoring with cardiac MRI, and monitoring with repeated echocardiography in people with heart failure who also have atrial fibrillation?
The clinical and cost effectiveness of biomarker-based monitoring, monitoring with cardiac MRI, and monitoring with repeated echocardiography in people with heart failure who also have atrial fibrillation is still being researched. The primary outcomes being studied include mortality, quality of life at 12 months, and unplanned hospitalisations. The important outcomes being studied include adverse events such as hypotension, hyperkalaemia, renal function, bradycardia, and arrhythmic events.